Alkermes Investor Relations Material
Latest events
Q1 2025
Alkermes
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alkermes plc
Access all reports
Alkermes plc is a biopharmaceutical company engaged in the development, manufacturing, and commercialization of innovative medicines. The company focuses on therapies for central nervous system disorders, including schizophrenia, bipolar disorder, and addiction, as well as treatments for other chronic diseases. Alkermes serves the healthcare sector by advancing solutions that address unmet medical needs. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Key slides for Alkermes plc
Q4 2024
Alkermes plc
Q1 2025
Alkermes plc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ALKS
Country
🇺🇸 United States